Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06580223 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma

StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: Jul 1, 2025 to Sep 1, 2025 Primary completion date: Jul 1, 2027 to Sep 1, 2027v3 Show 1 more changeShow less
    • Primary completion date: Jul 1, 2027 to Sep 1, 2027
  2. Start date: Sep 1, 2024 to Jul 1, 2025v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this study is to evaluate the efficacy and safety of aspirin and rivaroxaban in thromboprophylaxis in Chinese MM patients at high risk for MM-associated VTE.
Trial Details
NCT Number NCT06580223
Lead Sponsor Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Conditions Multiple Myeloma, Venous Thromboembolism
Enrollment 530 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov